BIOPARTNERS CAPITAL
BIOPARTNERS CAPITAL
Status:
Closed
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2009-11-11 | Cellerix | Biopartners Capital investment in Series B - Cellerix | 27 M EUR |
| 2002-02-26 | AM Pharma | Biopartners Capital investment in Series B - AM Pharma | N/A |
| 2001-08-09 | AM Pharma | Biopartners Capital investment in Series A - AM Pharma | 640 K EUR |
More informations about "Biopartners Capital"
Westlake BioPartners | Biotech Venture Capital Firm
May 14, 2025 Westlake BioPartners is a people-first life science VC firm that crafts companies around world-class entrepreneurs. Immersed in the Los Angeles biotech community we helped …See details»
Nucleate
Nucleate is a student-led organization that represents the largest global community of bio-innovators. ... RA Capital. Cami Samuels. Venrock. Steve Quake. Stanford University. Ellie …See details»
BioPartners 2025 Company Profile: Valuation, Investors
Global Healthcare Partners and aPriori Capital Partners have invested in BioPartners. When was BioPartners acquired? BioPartners was acquired on 09-Mar-2007. Who acquired BioPartners? …See details»
Our People | Biotech Investors | Westlake BioPartners
Westlake BioPartners is a tightly-woven team of investment, scientific, and operational experts who get hands on alongside entrepreneurs to navigate trials and celebrate triumphs. ... People …See details»
Princeton Biopartners
Data-Driven, Patient-Centered, Outcome-Focused Our mission is to improve the evidence base, accessibility, and dissemination of biomedical innovations through strategic advisory, software, …See details»
About Westlake | Life Science Venture Capital Firm
Westlake BioPartners is a life science venture capital firm where every aspect of our approach is founded on the understanding that people are paramount to success. We empower …See details»
Bios Partners
Bios Partners is a venture capital firm identifying advanced biotech in overlooked and under-invested markets in the U.S., which our team helps cultivate and bring to market. Geographic …See details»
Biopartners Capital — 3 Investments, 1 Exits, 2 Portfolio companies ...
Biopartners Capital. Search. Overview Investments Unlock datapoints. Portfolio analytics Team News & Media. Add fund to favorites. Save this fund for later to form your own custom list of …See details»
Executive Team - Arch Biopartners
Mar 5, 2019 Mr. Muruve became CEO of Arch Biopartners Inc. in 2010 after successfully co-founding and guiding the company through the transition to become publicly listed in Canadian …See details»
Westlake Village BioPartners - Crunchbase
Westlake Village BioPartners is a venture capital firm focused on incubating and building life sciences companies with entrepreneurs that have the potential to bring transformative …See details»
Westlake Village BioPartners launches $450 mln fund for biotechs
Jul 17, 2023 Venture capital firm Westlake Village BioPartners on Monday launched a $450 million fund to back early-stage biotech companies, at a time when high interest rates have …See details»
Biopartners Capital - Investments, Portfolio & Company Exits
Biopartners Capital was added in 2010.See details»
Borealis Biosciences Appoints Christian Hordo as CEO and …
Dec 19, 2024 Borealis is backed by founding investor Versant Ventures, Novartis and Westlake BioPartners, and has entered into a strategic research collaboration with Novartis. Borealis’ …See details»
Shares for Interest Debt Settlement – Arch Biopartners
TORONTO, Feb. 03, 2025 (GLOBE NEWSWIRE) — Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that the Company …See details»
Our Portfolio | Startup Biotech Companies | Westlake BioPartners
At Westlake BioPartners, we’re committed to empowering the founders and their companies that are discovering and developing the most promising new medicines. Building on these trusted …See details»
Advisors - GSAS Harvard Biotech Club
Peter Kolchinsky (Ph.D ’01) is co-founder, Managing Director, and Portfolio Manager of RA Capital Management, a multi-stage investment manager dedicated to evidence-based …See details»
bluebird bio Announces Completion of Acquisition by Carlyle and …
SOMERVILLE, Mass.--(BUSINESS WIRE)--Jun. 2, 2025-- bluebird bio (NASDAQ: BLUE) (“bluebird”), a pioneer in gene therapies for severe genetic diseases, today announced the …See details»
Board of Directors and Advisors – Arch Biopartners
From 2010 to 2012, Mr. Smith led the Finance and Business Development organization for Region Latin America and in 2013 moved to France as CFO for France and BeLux. In 2016, …See details»
bluebird bio Announces Completion of Acquisition by Carlyle and …
3 days ago SOMERVILLE, Mass. — June 2, 2025 — bluebird bio (NASDAQ: BLUE) (“bluebird”), a pioneer in gene therapies for severe genetic diseases, today announced the completion of …See details»
Shares for Interest Debt Settlement - GlobeNewswire
TORONTO, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that the Company …See details»